The term 'undruggable' was coined to describe proteins that could not be targeted pharmacologically. However, progress is being made to 'drug' many of these targets, and therefore more appropriate terms might be 'difficult to drug' or 'yet to be drugged'. Many desirable targets in cancer fall into this category, including the RAS and MYC oncogenes, and pharmacologically targeting these intractable proteins is now a key challenge in cancer research that requires innovation and the development of new technologies. In this Viewpoint article, we asked four scientists working in this field for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.

创造了“不可吸收的”一词来描述无法在药理学上靶向的蛋白质。但是，在“毒品”这些目标中的许多方面都正在取得进展，因此，更合适的术语可能“难以毒品”或“尚待毒品”。癌症中的许多理想靶点都属于这一类，包括RAS和MYC癌基因，并且以药理学靶向这些难治的蛋白质现在已成为癌症研究中的一项主要挑战，需要创新和开发新技术。在此观点文章中，我们请该领域的四位科学家就最重要的进展，这一重要研究领域的挑战以及未来前景发表意见。